Soft tissue sarcomas (STS) comprise a heterogeneous and rare group of tumors derived from mesenchymal cells that can rise in any anatomic site and present with diverse biological behaviors. Radical surgery was a common procedure for STS and used to be the standard treatment for many years. However, despite good results regarding local control (LC), it had poor functional outcomes. Nowadays amputations are rarely needed, and the treatment is always multidisciplinary. Many papers have been published on the use of conservative surgery (CS) associated with adjuvant treatments using radiotherapy (RT) and chemotherapy (CT), reporting the possibility of avoiding radical surgeries, maintaining the same results of LC and better quality of life than amputations. Exclusive resection is indicated in lowgrade superficial tumors or in small intramuscular tumors. There are benefits of using neoadjuvant and adjuvant RT; however neoadjuvant RT is associated with a higher incidence of healing difficulties, while adjuvant RT is associated with a higher incidence of fibrosis. RT is indicated for almost all cases of STS. Advanced technology RT is associated with greater LC and lower morbidity than conventional RT and brachytherapy (BRT). CT is not routinely used adjutancy but may be employed in highgrade tumors, or tumors greater than 5 cm. Neoadjuvant CT may have benefits through early treatment of micrometastases and increased resectability rates. New drugs such as targeted therapy, monoclonal antibodies and immunotherapy are under investigation. [ABSTRACT FROM AUTHOR]